Ioxaglate Versus IoDixanol for the Prevention of Contrast-Induced Nephropathy: The IDPC Trial

J Invasive Cardiol. 2023 Jun;35(6):E281-E290. Epub 2023 May 16.

Abstract

Background: Despite the potential benefits of percutaneous procedures for the assessment and treatment of coronary artery disease, these interventions require the use of iodine contrast, which might lead to contrast-induced nephropathy (CIN) and increased risk of dialysis and major adverse cardiac events (MACE).

Aims: We sought to compare two different iodine contrasts (low vs. iso-osmolar) for the prevention of CIN among high-risk patients.

Methods: This is a single-center, randomized (1:1) trial comparing consecutive patients at high risk for CIN referred to percutaneous coronary diagnostic and/or therapeutic procedures with low (ioxaglate) vs. iso-osmolarity (iodixanol) iodine contrast. High risk was defined by the presence of at least one of the following conditions: age >70 years, diabetes mellitus, non-dialytic chronic kidney disease, chronic heart failure, cardiogenic shock, and acute coronary syndrome (ACS). The primary endpoint was the occurrence of CIN, defined as a >25% relative increase and/or >0.5 mg/dL absolute increase in creatinine (Cr) levels compared with baseline between the 2nd and 5th day after contrast media administration.

Results: A total of 2,268 patients were enrolled. Mean age was 67 years. Diabetes mellitus (53%), non-dialytic chronic kidney disease (31%), and ACS (39%) were highly prevalent. The mean volume of contrast media was 89 ml ± 48.6. CIN occurred in 15% of all patients, with no significant difference regarding the type of contrast used (iso = 15.2% vs. low = 15.1%, P>.99). Differences were not observed in specific subgroups such as diabetics, elderly, and ACS patients. At 30-day follow-up, 13 patients in the iso-osmolarity group and 11 in low-osmolarity group required dialysis (P =.8). There were 37 (3.3%) deaths in the iso-osmolarity cohort vs. 29 (2.6%) in the low-osmolarity group (P =.4).

Conclusion: Among patients at high risk for CIN, the incidence of this complication was 15%, and independent of the use of low- or iso-osmolar contrast.

Trial registration: ClinicalTrials.gov NCT02991742.

Keywords: contrast media; nephropathy; osmolarity; percutaneous coronary intervention.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Contrast Media / adverse effects
  • Coronary Angiography / adverse effects
  • Coronary Angiography / methods
  • Creatinine
  • Humans
  • Ioxaglic Acid* / adverse effects
  • Kidney Diseases* / chemically induced
  • Risk Factors
  • Triiodobenzoic Acids / adverse effects

Substances

  • Contrast Media
  • Creatinine
  • iodixanol
  • Ioxaglic Acid
  • Triiodobenzoic Acids

Associated data

  • ClinicalTrials.gov/NCT02991742